<DOC>
	<DOC>NCT00711269</DOC>
	<brief_summary>The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.</brief_summary>
	<brief_title>Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Main Patient meets DSMIV criteria for schizophrenia. Patient is 18 or older but younger than 75 years of age on the day of signing informed consent. Patient understands the objectives, nature, and other aspects of the study and voluntarily agrees to participate in the study by providing written informed consent. Main Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus. Patient has Parkinson's disease. Patient has a history or complication of malignancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>